Chinese Journal of Dermatology ›› 2025, e20220878.doi: 10.35541/cjd.20220878
• Reviews • Previous Articles Next Articles
Ma Jing, Luan Chao, Chen Kun
Received:2022-12-07
Revised:2024-02-26
Online:2025-01-24
Published:2025-11-04
Contact:
Chen Kun
E-mail:kunchen181@aliyun.com
Ma Jing, Luan Chao, Chen Kun. Lipid metabolism-related proteins in psoriasis[J]. Chinese Journal of Dermatology,2025,e20220878. doi:10.35541/cjd.20220878
| [1] | Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence[J]. J Invest Dermatol, 2013,133(2):377⁃385. doi: 10.1038/jid. 2012.339. |
| [2] | Gui XY, Yu XL, Jin HZ, et al. Prevalence of metabolic syndrome in Chinese psoriasis patients: a hospital⁃based cross⁃sectional study[J]. J Diabetes Investig, 2018,9(1):39⁃43. doi: 10.1111/jdi.12663. |
| [3] | Hsu S, Green LJ, Lebwohl MG, et al. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials[J]. Br J Dermatol, 2020,182(4):880⁃888. doi: 10.1111/bjd.18327. |
| [4] | Owczarczyk⁃Saczonek A, Purzycka⁃Bohdan D, Nedoszytko B, et al. Pathogenesis of psoriasis in the "omic" era. Part Ⅲ. Metabolic disorders, metabolomics, nutrigenomics in psoriasis[J]. Postepy Dermatol Alergol, 2020,37(4):452⁃467. doi: 10.5114/ada.2020.98284. |
| [5] | Teklu M, Parel PM, Mehta NN. Psoriasis and cardiometabolic diseases: the impact of inflammation on vascular health[J]. Psoriasis (Auckl), 2021,11:99⁃108. doi: 10.2147/PTT.S320016. |
| [6] | Peralta C, Hamid P, Batool H, et al. Psoriasis and metabolic syndrome: comorbidities and environmental and therapeutic implications[J]. Cureus, 2019,11(12):e6369. doi: 10.7759/cureus.6369. |
| [7] | Kovács D, Fazekas F, Oláh A, et al. Adipokines in the skin and in dermatological diseases[J]. Int J Mol Sci, 2020,21(23):9048. doi: 10.3390/ijms21239048. |
| [8] | Hu D, Yang Y, Peng DQ. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin⁃naive patients with coronary artery disease[J]. Int J Cardiol, 2017,227:61⁃65. doi: 10.1016/j.ijcard. 2016.11.064. |
| [9] | Luan C, Chen X, Zhu Y, et al. Potentiation of psoriasis⁃like inflammation by PCSK9[J]. J Invest Dermatol, 2019,139(4):859⁃867. doi: 10.1016/j.jid.2018.07.046. |
| [10] | Zhang R, Wang YH, Shi X, et al. Sortilin regulates keratinocyte proliferation and apoptosis through the PI3K⁃AKT signaling pathway[J]. Life Sci, 2021,278:119630. doi: 10.1016/j.lfs.2021. 119630. |
| [11] | Garshick MS, Baumer Y, Dey AK, et al. Characterization of PCSK9 in the blood and skin of psoriasis[J]. J Invest Dermatol, 2021,141(2):308⁃315. doi: 10.1016/j.jid.2020.05.115. |
| [12] | Gao Y, Lu J, Bao X, et al. Inhibition of phospholipases suppresses progression of psoriasis through modulation of inflammation[J]. Exp Biol Med (Maywood), 2021,246(11):1253⁃1262. doi: 10.1177/1535370221993424. |
| [13] | Shao S, Chen J, Swindell WR, et al. Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris[J]. JCI Insight, 2021,6(20):e151911 [pii]. doi: 10.1172/jci.insight.151911. |
| [14] | Singh R, Chen YL, Ng SW, et al. Phospholipase activity of acyloxyacyl hydrolase induces IL⁃22⁃producing CD1a⁃autoreactive T cells in individuals with psoriasis[J]. Eur J Immunol, 2022,52(3):511⁃524. doi: 10.1002/eji.202149485. |
| [15] | Sparks CE, Sparks RP, Sparks JD. The enigmatic role of sortilin in lipoprotein metabolism[J]. Curr Opin Lipidol, 2015,26(6):598⁃600. doi: 10.1097/MOL.0000000000000244. |
| [16] | Nowowiejska J, Baran A, Krahel JA, et al. Serum cholesteryl ester transfer protein (CETP) and sortilin (SORT) in patients with psoriasis with relation to systemic treatment[J]. Metabolites, 2022,12(4):340. doi: 10.3390/metabo12040340. |
| [17] | Duvetorp A, Olsen RS, Nyström H, et al. Expression of low⁃density lipoprotein⁃related receptors 5 and 6 (LRP5/6) in psoriasis skin[J]. Exp Dermatol, 2017,26(11):1033⁃1038. doi: 10.1111/exd.13362. |
| [18] | Pasmatzi E, Papadionysiou C, Monastirli A, et al. Galectin 1 in dermatology: current knowledge and perspectives[J]. Acta Dermatovenerol Alp Pannonica Adriat, 2019,28(1):27⁃31. |
| [19] | Pasmatzi E, Papadionysiou C, Monastirli A, et al. Galectin 3: an extraordinary multifunctional protein in dermatology. Current knowledge and perspectives[J]. An Bras Dermatol, 2019,94(3):348⁃354. doi: 10.1590/abd1806⁃4841.20198426. |
| [20] | Corrêa MP, Correia⁃Silva RD, Sasso G, et al. Expression pattern and immunoregulatory roles of galectin⁃1 and galectin⁃3 in atopic dermatitis and psoriasis[J]. Inflammation, 2022,45(3):1133⁃1145. doi: 10.1007/s10753⁃021⁃01608⁃7. |
| [21] | Shih CM, Huang CY, Wang KH, et al. Oxidized low⁃density lipoprotein⁃deteriorated psoriasis is associated with the upregulation of lox⁃1 receptor and IL⁃23 expression in vivo and in vitro[J]. Int J Mol Sci, 2018,19(9):2610. doi: 10.3390/ijms19092610. |
| [22] | Wang H, Yang G, Zhang Q, et al. Apremilast ameliorates ox⁃LDL⁃induced endothelial dysfunction mediated by KLF6[J]. Aging (Albany NY), 2020,12(19):19012⁃19021. doi: 10.18632/aging. 103665. |
| [23] | Gupta M, Mahajan VK, Mehta KS, et al. Peroxisome proliferator⁃activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?[J]. Arch Dermatol Res, 2015,307(9):767⁃780. doi: 10.1007/s00403⁃015⁃1571⁃1. |
| [24] | Sobolev V, Nesterova A, Soboleva A, et al. Analysis of PPARγ signaling activity in psoriasis[J]. Int J Mol Sci, 2021,22(16):8603. doi: 10.3390/ijms22168603. |
| [25] | Blunder S, Pavel P, Minzaghi D, et al. PPARdelta in affected atopic dermatitis and psoriasis: a possible role in metabolic reprograming[J]. Int J Mol Sci, 2021,22(14):7354. doi: 10. 3390/ijms22147354. |
| [26] | Hao Y, Zhu YJ, Zou S, et al. Metabolic syndrome and psoriasis: mechanisms and future directions[J]. Front Immunol, 2021,12:711060. doi: 10.3389/fimmu.2021.711060. |
| [27] | Oh YJ, Lim HK, Choi JH, et al. Serum leptin and adiponectin levels in Korean patients with psoriasis[J]. J Korean Med Sci, 2014,29(5):729⁃734. doi: 10.3346/jkms.2014.29.5.729. |
| [28] | Wang Y, Huo J, Zhang D, et al. Chemerin/ChemR23 axis triggers an inflammatory response in keratinocytes through ROS⁃sirt1⁃NF⁃κB signaling[J]. J Cell Biochem, 2019,120(4):6459⁃6470. doi: 10.1002/jcb.27936. |
| [29] | Zou Q, Si J, Guo Y, et al. Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta⁃analysis[J]. J Int Med Res, 2021,49(3):300060521100 2381. doi: 10.1177/03000605211002381. |
| [30] | Wang HM, Wu C, Jiang YY, et al. Retinol and vitamin A metabolites accumulate through RBP4 and STRA6 changes in a psoriasis murine model[J]. Nutr Metab (Lond), 2020, 17:5. doi: 10.1186/s12986⁃019⁃0423⁃y. |
| [31] | Shehata WA, Basha MA, Gayed IM, et al. Relationship between disease severity and fetuin⁃A levels in patients with psoriasis[J]. Indian J Dermatol Venereol Leprol, 2020,86(5):586⁃588. doi: 10.4103/ijdvl.IJDVL_355_19. |
| [32] | Aizawa N, Ishiuji Y, Tominaga M, et al. Relationship between the degrees of itch and serum lipocalin⁃2 levels in patients with psoriasis[J]. J Immunol Res, 2019,2019:8171373. doi: 10.1155/2019/8171373. |
| [33] | Chekol Abebe E, Tilahun Muche Z, Behaile T/Mariam A, et al. Role of fetuin⁃A in the pathogenesis of psoriasis and its potential clinical applications[J]. Clin Cosmet Investig Dermatol, 2022,15:595⁃607. doi: 10.2147/CCID.S356801. |
| [34] | 胡煜, 栾超, 练霓, 等. 银屑病患者血浆中前蛋白转化酶枯草溶菌素9的表达及对外周血CD4+ T细胞活化的影响[J]. 中华皮肤科杂志, 2019,52(2):90⁃93. doi: 10.3760/cma.j.issn.0412⁃4030.2019.02.004. |
| [1] | Committee on Psoriasis, Chinese Society of Dermatology. Expert proposal on apremilast for the treatment of psoriasis (2025 edition) [J]. Chinese Journal of Dermatology, 2025, 58(5): 416-424. |
| [2] | Li Ziyu, Lu Yan. Paying attention to severe skin diseases after COVID-19 [J]. Chinese Journal of Dermatology, 2025, 58(4): 378-383. |
| [3] | Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China (2025 version) [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306. |
| [4] | He Chunxia, Jin Hongzhong . Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies [J]. Chinese Journal of Dermatology, 2025, 58(4): 307-314. |
| [5] | Huang Shudai, Zhou Xuyue, Zhang Jiaan, Chen Kun. Role of specialized pro-resolving mediators in psoriasis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240503-e0240503. |
| [6] | Jin Zhe, Gao Dong. Application and prospect of exosomes in infection and inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240148-e20240148. |
| [7] | Zhang Liangliang, Zhang Jiaan, Chen kun . Pathogenesis and treatment of scalp psoriasis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240001-e20240001. |
| [8] | Li Xiuzhen, Xu Xiulian. Effects of interleukin-23 inhibitors on psoriasis comorbidities [J]. Chinese Journal of Dermatology, 2025, 58(3): 268-272. |
| [9] | Lianghong Chen Yan SUN Jing-Yu WANG. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2025, 58(3): 266-268. |
| [10] | Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell-derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220881-e20220881. |
| [11] | Wang Yujue, Li Qingyang, Wang Gang. Role of vascular endothelial cells in the pathogenesis of psoriasis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20250265-e20250265. |
| [12] | Zhang Xiaoxu, Luo Suju. Efficacy and safety of upadacitinib in the treatment of six cases of palmoplantar pustulosis [J]. Chinese Journal of Dermatology, 2025, 0(2): 20230772-e20230772. |
| [13] | Wei Lu, Wang Chang, Zhang Buxin, Xu Juntao, Wang Li, Wang Qingxing, Lu Lingling, Liu Aimin. Gender differences in psoriasis [J]. Chinese Journal of Dermatology, 2025, 58(12): 1188-1192. |
| [14] | Ye Hui, Xue Rujun, Zhang Xibao. Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis [J]. Chinese Journal of Dermatology, 2025, 58(12): 1192-1195. |
| [15] | Yuan Liyan, Yu Xiaoling, Wang Xiaohua, Yang Bin. Tyrosine kinase 2 inhibitors for plaque psoriasis: mechanisms of action and advances in clinical research [J]. Chinese Journal of Dermatology, 2025, 58(11): 1095-1098. |
|